More than half of patients with an advanced form of lung cancer initially responded to an experimental Amgen drug that targets a genetic driver of the disease.
During the World Conference on Lung Cancer in Barcelona, Amgen presented results of a study that found that the highest dose of experimental AMG 510 shrank tumors in seven of 13 patients based on their first imaging scans post-treatment.
The findings are the first in patients for a KRAS inhibitor focused on a mutation known as G12C, giving Amgen the lead against rivals such as Johnson & Johnson.
The U.S. FDA granted the AMG 510 fast-track status for patients with metastatic non-small cell lung cancer with the G12C mutation.
Read the Bloomberg coverage